The swift seizure by the U.S. of Venezuela’s president ranks alongside other epoch-defining events that spells the end of a traditional asset allocation model, a team of strategists argue. A team of ...

Oracle (ORCL) has shown significant rallies in its history. In 2025, it experienced more than a 50% increase within two months. Moreover, there were seven occasions when ORCL appreciated over 30% in ...

Manhattan: NASA creates a solar dreidel drone. A horrible bitching session breaks out in Macy’s window between staff who want the star on the tree to have five points and staff who want six. The ...

Volatility will remain a feature of the cryptocurrency market, making appropriate portfolio allocation sizing a key decision for investors. The introduction of many ETFs covering leading cryptos like ...

Edward Khomotso Nkadimeng receives funding from the National Research Foundation. In most industries, maintenance is a waiting game. Things are fixed when they break. But in the 21st century, an age ...

Broadcom‘s stock has increased by 106% in the last year, greatly outshining its competitors amid the AI and data-center surge. But how does this leader in AI infrastructure truly stack up against its ...

If your custom GPT is a frustrating waste of time, the problem isn’t the AI. It’s your process. Here’s how to build a high-performance digital asset in hours, not weeks. To build an AI assistant that ...

The flagship Gemini 3 Pro model is coming to the Gemini app and Search, with improvements across coding, reasoning, and less ‘flattery.’ The flagship Gemini 3 Pro model is coming to the Gemini app and ...

After years of narrowing wage inequality, the workplace has become a tale of two economies again. This time, unlike in the postpandemic period, trends favor the top 25% of the U.S. workforce, whose ...

Art is a legitimate but illiquid asset class offering diversification and enjoyment. Only top-quality works drive returns, making access and research essential. NFTs and digital art remain volatile ...

Less than two years after laying out plans to divest its China operations and become a U.S.-focused biotech, I-Mab Biopharma is re-staking its claim in the Asia-Pacific region. The drugmaker mapped ...